HK:1349 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic technical platform drugs, including recombinant human TNF receptor 2-Fc fusion protein mutant, which is in Phase I clinical trials for the treatment of arthritis; CD30-MMAE, which is in pre-clinical studies for tumors; Anti-sclerostin mab that is in pre-clinical studies for osteoporosis; and Avastin, which has completed pre-clinical study for tumors. The company also provides photodynamic technical platform drugs, such as Hemoporfin for port wine stain; Deuteroporphyrin that is in Phase II clinical trials for tumors; Aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV; and Aminolevulinic acid that has submitted application for clinical trials for acne, as well as is in pre-clinical studies for brain gliomas and basal cell carcinoma. In addition, it offers Nano technical platform drugs comprising Vincristine sulphate liposome, which has completed Phase I clinical trials for tumors; and Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company is developing food safety inspection projects, as well as researches and develops biological and medical technology, pharmaceutical projects, and medical diagnostic products. Additionally, it engages in the provision of medical investment management, health industry management, projects investment, assets management, investment and business consultation, and medical and enterprise management consultation activities. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

3.13 HKD
As of 08/12/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  
Index country:  China
Country of incorporation:  China
IPO date:  08/13/2002
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   0 HKD
Current dividend yield:   0.00%
Sedol:      6540470

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy